vorapaxar + clopidogrel

Vorapaxar + clopidogrel is a combination of two oral antiplatelet agents used to reduce the risk of atherothrombotic events such as heart attack and stroke in patients with a history of myocardial infarction or peripheral arterial disease. Vorapaxar is a first-in-class protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation by selectively blocking PAR-1 on platelets[1][6][8]. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 subtype of adenosine diphosphate (ADP) receptor on platelets, thereby preventing platelet aggregation[4]. The combination may be used in secondary prevention settings for patients at high risk for cardiovascular events. Vorapaxar was developed by Schering-Plough (now Merck & Co.), while clopidogrel was developed by Sanofi and Bristol Myers Squibb[6].